Abiopharma

🔍 RUIZ WALLACE D (Executive)

Company: Inuvo, Inc. (INUV)

Report Date: 2026-04-01

Detailed Transactions and Holdings:

• Acquired 7,500 shares of Common Stock (Direct)
  Date: 2026-04-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 130,106.00 | transaction_form_type: 4
• Sold 3,739 shares of Common Stock at $2.14 per share (Direct)
  Date: 2026-04-01 | Code: F | equity_swap_involved: 0 | shares_owned_after: 126,367.00 | transaction_form_type: 4
• Sold 7,500 shares of Restricted Stock Unit (Derivative)
  Date: 2026-04-01 | Code: M | Expires: 2026-04-01 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F2, F3

Footnotes:

• F1: Each restricted stock unit represents a contingent right to receive one share of Issuer's Common Stock.
• F2: The restricted stock units become vested 33.33% per year beginning on the first anniversary of the date of grant.
• F3: Adjusted to reflect a 1-for-10 reverse stock split that occurred on June 10, 2025.